サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1542861

腎ファンコニ症候群の世界市場：2024年～2031年

Global Renal Fanconi Syndrome Market - 2024-2031

出版日
ページ情報
英文 181 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
腎ファンコニ症候群の世界市場：2024年～2031年
出版日: 2024年08月26日
発行: DataM Intelligence
ページ情報: 英文 181 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

概要

世界の腎ファンコニ症候群市場は、2023年に5億7,640万米ドルに達し、2031年には7億6,750万米ドルに達すると予測され、予測期間2024年にはCAGR 3.7%で成長する見込みです。

ファンコニ症候群は、様々な電解質や通常近位尿細管で吸収される物質の吸収不良を引き起こす近位尿細管の欠陥です。先天性または後天性の疾患である可能性があります。成人のファンコニ症候群は一般的に後天性のタイプであり、小児のファンコニ症候群は一般的に遺伝性のタイプです。ファンコニ症候群の治療法は、その特定の病因によって異なり、通常、根本的な原因が存在する場合はその原因に対処し、体積不足、栄養不足、電解質不足を改善する必要があります。ファンコニ症候群」の定義は、尿細管における全体的な欠損を意味します。尿細管が通常再吸収する溶質が何であれ、この症候群の患者では十分に再吸収されないです。

この病態で観察される水と電解質の喪失は、口渇、疲労、脱力感、多尿を引き起こします。低リン血症は、特に血清リン濃度が1mg/dL未満になると、さまざまな徴候や症状を引き起こします。知覚異常、振戦、筋力低下などの神経筋症状がみられることがあります。重度の低リン血症は心筋収縮力を低下させるが、臨床的なうっ血性心不全に至ることはまれです。また、患者の機械的人工呼吸からの離脱能力を損なうこともあります。

市場力学：

促進要因

腎症候群の有病率の増加

腎ファンコニ症候群市場の需要は、複数の要因によって牽引されています。腎ファンコニ症候群の有病率の上昇は、市場の成長を促進します。最近では、新規治療薬の進歩が目覚ましく、症候群やそのスクリーニング方法に対する認識が高まっています。これらは、腎ファンコニ市場の主要な促進要因となっています。

米国腎臓基金によると、腎症候群は憂慮すべき速度で増加しています。現在、成人の7人に1人が罹患しており、これはアメリカの成人の約14％に相当します。全米腎臓財団によると、腎症候群は男性よりも女性に多いです。女性では14％、男性では12％です。世界全体では、約10％の人が慢性腎症候群に罹患しています。

阻害要因

治療に伴う高額な費用、頻繁なモニタリング、熟練した専門家の不足、専門的な治療の必要性、生涯にわたる投薬とモニタリングなどの要因が市場の妨げになると予想されます。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 腎症候群の有病率の増加
      • 新規治療薬の進歩
    • 症候群とそのスクリーニングに関する意識の高まり
      • 治療に伴う高コスト
      • 熟練した専門家の不足
      • 専門的治療、生涯投薬、モニタリングの必要性
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • アンメットニーズ
  • PESTEL分析
  • 特許分析
  • SWOT分析

第6章 疾患タイプ別

  • 遺伝性
  • 後天性
  • 治療別
  • シスチン症の治療
  • 対症療法
  • 食生活の改善と調整
  • 抗生物質投与
  • 腎臓移植
  • サプリメント

第7章 投与経路別

  • 経口
  • 静脈内

第8章 流通チャネル別

  • 病院薬局
  • 小売薬局
  • オンライン薬局
  • その他

第9章 エンドユーザー別

  • 病院
  • 専門クリニック
  • 在宅医療
  • その他

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋地域
  • 中東・アフリカ

第11章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第12章 企業プロファイル

  • Centogene
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な発展
  • Gilead sciences
  • Teva Pharmaceuticals
  • Manus Akkteva Biopharma
  • PV Pharma Healthcare
  • Medyra Pharmaceuticals
  • Merck KgaA
  • Aurisco Pharmaceuticals
  • AbbVie Inc.
  • Pfizer

第13章 付録

目次
Product Code: PH8543

Overview

The Global Renal Fanconi Syndrome market reached US$ 576.4 million in 2023 and is expected to reach US$ 767.5 million by 2031, growing at a CAGR of 3.7% during the forecast period 2024-2031.

Fanconi syndrome is a defect of the proximal tubule leading to malabsorption of various electrolytes and substances that are usually absorbed by the proximal tubule. It could be an inherited or acquired condition. Adults with Fanconi syndrome typically have the acquired type, and children with the syndrome typically have the genetic type. The ability to treat the condition depends on its particular etiology and typically involves addressing the underlying cause, if one exists, and correcting volumetric, nutritional, or electrolytic deficiencies. The definition of "Fanconi syndrome" implies a global defect in the tubule. Whatever solutes the tubule normally reabsorbs do not get reabsorbed adequately in a patient with this syndrome.

The loss of water and electrolytes observed in this condition would cause thirst, fatigue, weakness, and polyuria. Hypophosphatemia causes a variety of signs and symptoms, especially if the serum phosphorus level gets below 1 mg/dL. Neuromuscular symptoms such as paresthesia, tremor, and muscle weakness may be noted. Severe hypophosphatemia may impair myocardial contractility though this rarely results in clinical congestive heart failure. It may also impair the ability of patients to be weaned from mechanical ventilation.

Market Dynamics: Drivers

Increasing prevalence of renal syndromes

The demand for the renal fanconi syndrome market is driven by multiple factors. The rising prevalence of renal syndromes propels the market growth. In recent times, there have been a lot of advancements in novel therapeutics and there is an increase in awareness about the syndrome and its screening procedures. These act as major driving factors in the renal fanconi market.

According to the American Kidney Fund, renal syndromes are growing at an alarming rate. It currently affects 1 in 7 adults, which is around 14% of the adults in America. According to the National Kidney Foundation, renal syndromes are found to be more common in women than in men. That is 14% in women and 12% in men. In the entire global population, around 10% of the people are affected by chronic renal syndromes.

Restraints

Factors such as high cost associated with the treatment, frequent monitoring, shortage of skilled professionals, need for specialized treatments, and lifetime medication and monitoring are expected to hamper the market.

Segment Analysis

The renal fanconi disorder market is segmented based on disease type, treatment, route of administration, distribution channel, end-user, and region.

The segment acquired renal fanconi syndrome accounted for approximately 56.4% of the renal fanconi syndrome market share

The acquired renal fanconi segment is expected to hold the largest market share over the forecast period. According to medlineplus.gov, the acquired renal fanconi syndrome is due to the regular medication of azathioprine, cidofovir, gentamicin, and tetracycline, exposure to heavy metals, light chain deposition disease, primary amyloidosis, and multiple myeloma.

The adult-acquired fanconi syndrome is a condition in which the proximal tube becomes defective. The proximal tube leads to the malabsorption of electrolytes and other substances such as water, sodium, potassium, chloride, glucose, amino acids, and bicarbonates which are generally absorbed by the proximal tube of the nephron. According to NIH.gov, the general measures that must be taken to reduce the impact of acquired renal fanconi syndrome are that dehydration must be avoided and should stay hydrated all the time, and lost electrolytes and substances like potassium, phosphates, and bicarbonates must be replaced from time to time.

Heavy metals such as lead are one of the major causes of acquired renal fanconi syndrome. So, avoiding exposure to lead helps in the prevention of acquired renal fanconi syndrome.

Geographical Analysis

North America accounted for approximately 43.5% of the renal fanconi Syndrome Market Share

North America region is expected to hold the largest market share over the forecast period. The rising incidence of renal syndromes at an alarming rate, and growing awareness among people, in this region, help to propel the market. According to the National Kidney Foundation, in recent times approximately 15% of the adults in the region of North America are affected by renal syndromes. The kidney syndromes are the leading cause of death in this region. Approximately 1 in 3 adults with diabetes and 1 in 5 adults with high blood pressure may have kidney disease.

The presence of major players and pharmaceutical industries that are involved in the manufacture of medicines that are used in the treatment of renal syndromes are located and developed in this region. Technological advancements in the healthcare sector are increasing day by day in this region which leads to the largest market share of this region in North America.

The awareness about renal fanconi syndrome and other renal syndromes is increasing day by day, which is one of the causes of the largest market share of this region. Development in research techniques and advancements in novel therapeutics like supportive therapies, gene therapy, and enzyme replacement therapy are increasing. All these factors together accounted for the largest market share in this geographical region.

Market Segmentation

By Disease Type

  • Inherited(genetic)
  • Acquired

By Treatment

  • Cystinosis treatment
  • Symptomatic management
  • Dietary changes and adjustments
  • Antibiotics
  • Kidney transplantation
  • Supplements

By Route of Administration

  • Oral
  • Intravenous

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

By End-User

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa

Competitive Landscape

The major global players in the renal fanconi syndrome market include Centogene, Gilead Sciences, Teva Pharmaceuticals, Manus Akkteva Biopharma, PV Pharma Healthcare, Medyra Pharmaceuticals, Merck KgaA, Aurisco Pharmaceuticals, AbbVie Inc., Pfixer Ltd among others.

Key Developments

  • On March 2, 2021, Teva Pharmaceuticals got into an acquisition with Actavis generics. This strategic acquisition brings together two leading generics businesses with complementary strengths, R&D capabilities, product pipelines and portfolios, geographical footprints, operational networks, and cultures. The result is a stronger, more competitive Teva, well positioned to thrive in an evolving global marketplace, to realize the opportunities the very attractive global and U.S. generics markets offer, and to deliver the highest-quality generic medicines at the most competitive prices, unlocking value to patients, healthcare systems and investors around the world.
  • On December 1, 2022, Merck acquired all the shares of Erbi Biosystems. Erbi is the developer of Breez, one of the few micro-scale, fully automated, functionally closed, and continuous perfusion cell culture platform technologies on the market. By integrating Breez into its existing Mobius portfolio, Merck can offer a full range of bioreactors, cell retention systems, and devices as well as cell culture media. The business is allocated to the Process Solutions business unit in the Life Science business sector.

Why Purchase the Report?

  • To visualize the renal fanconi syndrome market segmentation based on disease type, treatment, route of administration, distribution channel, end-user, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development
  • Excel data sheet with numerous data points of renal fanconi syndrome market level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping is available in Excel consisting of key products of all the major players.

The renal fanconi syndrome market report would provide approximately 51 tables, 54 figures, and 181 Pages.

Target Audience 2024

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Disease type
  • 3.2. Snippet by Treatment
  • 3.3. Snippet by Route of Administration
  • 3.4. Snippet by Distribution Channel
  • 3.5. Snippet by End-User
  • 3.6. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Prevalence of Renal Syndromes
      • 4.1.1.2. Advancements in Novel Therapeutics
    • 4.1.2. Increase in Awareness about the Syndrome and its Screening

Restraints

      • 4.1.2.1. High Cost Associated with the Treatment
      • 4.1.2.2. Shortage of skilled professionals
      • 4.1.2.3. Need for specialized treatments, lifetime medication, and monitoring
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Unmet Needs
  • 5.6. PESTEL Analysis
  • 5.7. Patent Analysis
  • 5.8. SWOT Analysis

6. By Disease Type

    • 6.1.1. Introduction
    • 6.1.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 6.1.3. Market Attractiveness Index, By Disease Type
  • 6.2. Inherited(genetic)*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Acquired
  • 6.4. By Treatment
    • 6.4.1. Introduction
    • 6.4.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 6.4.3. Market Attractiveness Index, By Treatment
  • 6.5. Cystinosis Treatment*
    • 6.5.1. Introduction
    • 6.5.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.6. Symptomatic management
  • 6.7. Dietary changes and adjustments
  • 6.8. Antibiotics
  • 6.9. Kidney transplantation
  • 6.10. Supplements

7. By Route of Administration

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 7.1.2. Market Attractiveness Index, By Route of Administration
  • 7.2. Oral*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Intravenous

8. By Distribution Channel

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 8.1.2. Market Attractiveness Index, By Distribution Channel
  • 8.2. Hospital Pharmacy*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Retail Pharmacy
  • 8.4. Online Pharmacy
  • 8.5. Others

9. By End-User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.1.2. Market Attractiveness Index, By End-User
  • 9.2. Hospitals*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Specialty Clinics
  • 9.4. Homecare
  • 9.5. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of administration
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.8.1. U.S.
      • 10.2.8.2. Canada
      • 10.2.8.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.8.1. Germany
      • 10.3.8.2. UK
      • 10.3.8.3. France
      • 10.3.8.4. Italy
      • 10.3.8.5. Spain
      • 10.3.8.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.8.1. Brazil
      • 10.4.8.2. Argentina
      • 10.4.8.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.8.1. China
      • 10.5.8.2. India
      • 10.5.8.3. Japan
      • 10.5.8.4. South Korea
      • 10.5.8.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Centogene *
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Gilead sciences
  • 12.3. Teva Pharmaceuticals
  • 12.4. Manus Akkteva Biopharma
  • 12.5. PV Pharma Healthcare
  • 12.6. Medyra Pharmaceuticals
  • 12.7. Merck KgaA
  • 12.8. Aurisco Pharmaceuticals
  • 12.9. AbbVie Inc.
  • 12.10. Pfizer

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us